APA (7th ed.) Citation

Hayato, S., Takenaka, O., Sreerama Reddy, S. H., Landry, I., Reyderman, L., Koyama, A., . . . Hussein, Z. (2022). Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease. CPT: pharmacometrics and systems pharmacology, 11(12), 1578-1591. https://doi.org/10.1002/psp4.12862

Chicago Style (17th ed.) Citation

Hayato, Seiichi, Osamu Takenaka, Sree Harsha Sreerama Reddy, Ishani Landry, Larisa Reyderman, Akihiko Koyama, Chad Swanson, Sanae Yasuda, and Ziad Hussein. "Population Pharmacokinetic‐pharmacodynamic Analyses of Amyloid Positron Emission Tomography and Plasma Biomarkers for Lecanemab in Subjects with Early Alzheimer's Disease." CPT: Pharmacometrics and Systems Pharmacology 11, no. 12 (2022): 1578-1591. https://doi.org/10.1002/psp4.12862.

MLA (9th ed.) Citation

Hayato, Seiichi, et al. "Population Pharmacokinetic‐pharmacodynamic Analyses of Amyloid Positron Emission Tomography and Plasma Biomarkers for Lecanemab in Subjects with Early Alzheimer's Disease." CPT: Pharmacometrics and Systems Pharmacology, vol. 11, no. 12, 2022, pp. 1578-1591, https://doi.org/10.1002/psp4.12862.